Cost-Effectiveness of Allergen Immunotherapy Evaluated

This article originally appeared here.
Share this content:
Cost-Effectiveness of Allergen Immunotherapy Evaluated
Cost-Effectiveness of Allergen Immunotherapy Evaluated

MONDAY, July 31, 2017 (HealthDay News) -- Allergen immunotherapy (AIT) may be cost-effective for allergic rhinitis, and for venom allergy in high-risk subgroups, according to research published online July 18 in Allergy.

Miqdad Asaria, Ph.D., from the University of York in the United Kingdom, and colleagues conducted systematic reviews to assess evidence on the effectiveness, safety, and cost-effectiveness of AIT for allergic rhinitis, allergic asthma, immunoglobulin E-mediated food allergy, and venom allergy. Twenty-three studies met the inclusion criteria.

Nineteen of the studies examined the cost-effectiveness of AIT in allergic rhinitis; seven of these were based on data from randomized controlled trials with economic evaluations conducted from the perspective of the health system. Based on the body of evidence, the researchers found that sublingual immunotherapy (SLIT) and subcutaneous immunotherapy would be considered cost-effective using the U.K. National Institute for Health and Clinical Excellence threshold of £20,000/quality-adjusted life-year (QALY). Data from three eligible studies suggested that SLIT may be cost-effective with an incremental cost-effectiveness ratio of £10,726 per QALY in patients with both asthma and allergic rhinitis. Based on one economic modeling study, for bee and wasp venom allergy, AIT is only likely to be cost-effective for very-high-risk groups who may have multiple exposures to venom/year.

"Overall, the evidence to support the cost-effectiveness of AIT is limited and of low methodological quality," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »